p-Carboxyphenoxyacetone | 18859-30-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-Carboxyphenoxyacetone
• 英文别名: 4-(2-Oxopropoxy)benzoic acid
• CAS: 18859-30-8
• 化学式: C₁₀H₁₀O₄
• mdl: MFCD13874797
• 分子量: 194.187
• InChiKey: GCRJLCRIYWGVRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  过氧化氢酶 、 一氯丙酮 生成 p-Carboxyphenoxyacetone
  参考文献：
  名称：

  不可逆酶抑制剂。CVII。蛋白水解酶。二。胰凝乳蛋白酶抑制剂复合物中的整体耐受性。

  摘要：

  DOI：

  10.1021/jm00318a031

文献信息

• Double-acylated GLP-1 derivatives
  申请人：Novo Nordisk A/S

  公开号：US10000542B2

  公开（公告）日：2018-06-19

  The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.

  本发明涉及一种GLP-1类似物的衍生物，该类似物包括第一个K残基和第二个K残基，分别位于与GLP-1（7-37）（SEQ ID NO：1）的位置26和37相对应的位置上，并且与GLP-1（7-37）相比最多有八个氨基酸变化；该衍生物包括通过连接剂连接到所述第一个和第二个K残基上的两个延长基团，其中所述延长基团选自Chem.1：HOOC-（CH2）x-CO-*和Chem.2：HOOC-C6H4-O-（CH2）y-CO-*，其中x为8-16的整数范围内的整数，y为6-13的整数范围内的整数；连接剂包括Chem.3：* -NH-（CH2）q-CH [（CH2）w-NR1R2] -CO- *，它在其CO- *端连接到GLP-1类似物的第一个或第二个K残基的epsilon氨基基团上，其中q为0-5的整数范围内的整数，R1和R2独立地表示* -H或* -CH3，w为0-5的整数范围内的整数；或其药学上可接受的盐，酰胺或酯。本发明还涉及其在治疗和/或预防所有形式的糖尿病和相关疾病中的药物应用，以及相应的新型肽和连接剂中间体。这些衍生物具有高效、稳定、持久和适合口服给药的特点。
• Arylalkylamine Compound and Process for Preparing the Same
  申请人：Miyazaki Hiroshi

  公开号：US20070225296A1

  公开（公告）日：2007-09-27

  The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.

  本发明涉及一种由以下公式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及上述化合物作为钙感受受体的激活化合物（CaSR激动剂），以及含有上述化合物作为有效成分的制药组合物等的用途。公式中的符号表示以下含义：Ar：此处为可选取代的芳基或可选取代的杂环芳基，其中杂环的环部分是一个含有1或2个杂原子的5-至6元单环杂环，与苯环融合；R1：选自可选取代的环烃基团和可选取代的杂环基团的群；n：1至3的整数；X：单键臂、—CH2—、—CO—、—（CH2）m—CO—、—CH（R2）—CO—、—（CH2）p—Y—（C（R3）（R4））q—CO—、—NH—CO—或—N（R5）—CO—；在上述各定义的X中，左端所描述的键臂表示与R1的键；m为1至3的整数；p为0至2的整数；q为0至2的整数；Y：—O—或—SO2—；R2：苯基或低碳烷基；R3、R4：各自独立地表示氢原子或低碳烷基；R5：低碳烷基；前提是由R1表示的基团的环部分既不是萘亚甲基也不是其部分饱和基团，且当X为—CH2—或—CO—时，R1不是萘基。
• ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME
  申请人：MIYAZAKI Hiroshi

  公开号：US20100249049A1

  公开（公告）日：2010-09-30

  The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R 1 : a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH 2 —, —CO—, —(CH 2 ) m —CO—, —CH(R 2 )—CO—, —(CH 2 ) p —Y—(C(R 3 )(R 4 )) q —CO—, —NH—CO— or —N(R 5 )—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO 2 —; R 2 : phenyl or lower alkyl; R 3 , R 4 : each independently represents hydrogen atom or lower alkyl; R 5 : lower alkyl; provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH 2 — or —CO—, R 1 is not naphthyl.

  本发明涉及一种由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，制备该化合物的方法，以及上述化合物作为钙感受受体（CaSR激动剂）的激活化合物、包含上述化合物作为有效成分的药物组合物等的用途。式中符号表示以下含义：Ar：可选取的取代芳基或可选取的取代杂环芳基，在此，所述杂环的环状部分是由1或2个杂原子的5-6元单环杂环与苯环融合而成的双环杂环；R1：选自可选取的取代环烃基团和可选取的取代杂环基团的群；n：为1至3的整数；X：单键连接臂，-CH2-，-CO-，-(CH2)m-CO-，-CH(R2)-CO-，-(CH2)p-Y-(C(R3)(R4))q-CO-，-NH-CO-或-N(R5)-CO-；在上述X的各自定义中，左端所述连接臂表示与R1的键合；m为1至3的整数；p为0至2的整数；q为0至2的整数；Y：-O-或-SO2-；R2：苯基或低碳烷基；R3，R4：各自独立地表示氢原子或低碳烷基；R5：低碳烷基；所述R1表示的基的环部分既不是萘亚甲基基团，也不是其部分饱和基团，当X为-CH2-或-CO-时，R1不是萘基。
• ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1757582B1

  公开（公告）日：2015-12-30
• Double-Acylated GLP-1 Derivatives
  申请人：Madsen Alice Ravn

  公开号：US20130288960A1

  公开（公告）日：2013-10-31

  The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH 2 ) x —CO—* Chem. 2: HOOC—C 6 H 4 -0-(CH 2 ) y —CO—* Chem. 3: R 2 —C 6 H 4 —(CH 2 ) z —CO—*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R 2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *—NH—(CH 2 ) 2 -(0-(CH 2 ) 2 ) k -0-(CH 2 ) n —CO—*. wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.